Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 16/20 | 0.78 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.71 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.71 |
| ▸ | EGFR | P00533 | 2/20 | 0.71 |
| ▸ | FYN | P06241 | 2/20 | 0.71 |
| ▸ | HCK | P08631 | 2/20 | 0.71 |
| ▸ | SRC | P12931 | 2/20 | 0.71 |
| ▸ | JAK3 | P52333 | 2/20 | 0.71 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.71 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.71 |
| ▸ | ABL1 | P00519 | 1/20 | 0.71 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.71 |
| ▸ | YES1 | P07947 | 1/20 | 0.71 |
| ▸ | LYN | P07948 | 1/20 | 0.71 |
| ▸ | FGR | P09769 | 1/20 | 0.71 |
| ▸ | KIT | P10721 | 1/20 | 0.71 |
| ▸ | BCR | P11274 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19205382 | 0.95 | LCK (0.69) | LCKMAPK14MAPK13EGFRFYN | |
| SCHEMBL30011130 | 0.92 | LCK (0.78) | LCKMAPK14MAPK13EGFRFYN | |
| SCHEMBL20975769 | 0.92 | LCK (0.78) | LCKMAPK14MAPK13EGFRFYN | |
| SCHEMBL774162 | 0.88 | LCK (1.00) | LCKMAPK14MAPK13EGFRFYN | |
| SCHEMBL773788 | 0.86 | LCK (0.81) | LCKMAPK14MAPK13EGFRFYN | |
| SCHEMBL1539971 | 0.86 | LCK (0.81) | LCKMAPK14MAPK13EGFRFYN | |
| SCHEMBL774786 | 0.86 | LCK (1.00) | LCKMAPK14MAPK13EGFRFYN | |
| SCHEMBL774932 | 0.85 | LCK (1.00) | LCKMAPK14MAPK13EGFRFYN | |
| SCHEMBL22038674 | 0.85 | LCK (0.69) | LCKMAPK14MAPK13EGFRFYN | |
| SCHEMBL12988918 | 0.84 | LCK (0.82) | LCKMAPK14MAPK13EGFRFYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3715346-B1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | DANA FARBER CANCER INST INC (US) | 2024-01-03 | — | — | EP | disclosed |
| US-10844077-B2 | Thiazolyl-containing compounds for treating proliferative diseases | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-11-24 | — | — | US | disclosed |
| US-10844077-B2 | Thiazolyl-containing compounds for treating proliferative diseases | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-11-24 | — | — | US | disclosed |
| EP-3715346-A1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | Dana-Farber Cancer Institute (US) | 2020-09-30 | — | — | EP | disclosed |
| US-20200165267-A1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-05-28 | — | — | US | disclosed |
| US-20200165267-A1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-05-28 | — | — | US | disclosed |
| EP-3209648-B1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | DANA FARBER CANCER INST INC (US) | 2020-03-11 | — | — | EP | disclosed |
| US-10464949-B2 | Thiazolyl-containing compounds for treating proliferative diseases | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-11-05 | — | — | US | disclosed |
| US-10464949-B2 | Thiazolyl-containing compounds for treating proliferative diseases | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-11-05 | — | — | US | disclosed |
| US-20190119301-A1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-04-25 | — | — | US | disclosed |
| US-20190119301-A1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-04-25 | — | — | US | disclosed |
| US-10112957-B2 | Thiazolyl-containing compounds for treating proliferative diseases | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-10-30 | — | — | US | disclosed |
| EP-3209648-A1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | Dana-Farber Cancer Institute, Inc. (US) | 2017-08-30 | — | — | EP | disclosed |
| US-20170233411-A1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-08-17 | — | — | US | disclosed |
| US-20170233411-A1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-08-17 | — | — | US | disclosed |
| US-20170233411-A1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200165267-A1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | BTK, BCL9L, MCL1 | LCK 11/4885MAPK14 657/4885MAPK13 605/4885 |
| US-20170233411-A1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | BTK, BCL9L, BCL9 | LCK 11/4885MAPK14 608/4885MAPK13 577/4885 |
| US-20190119301-A1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | BTK, BCL9L, BCL9 | LCK 11/4885MAPK14 608/4885MAPK13 577/4885 |
| US-10844077-B2 | Thiazolyl-containing compounds for treating proliferative diseases | BTK, BCL9L, MCL1 | LCK 11/4885MAPK14 657/4885MAPK13 605/4885 |
| US-10464949-B2 | Thiazolyl-containing compounds for treating proliferative diseases | BTK, BCL9L, BCL9 | LCK 11/4885MAPK14 608/4885MAPK13 577/4885 |
| US-10112957-B2 | Thiazolyl-containing compounds for treating proliferative diseases | BTK, BCL9L, BCL9 | LCK 11/4885MAPK14 608/4885MAPK13 577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.